nsc33353 identify screen national cancer institute nci diversity set iv mdamb231 cell nci diversity set iv library 1600 compound screen use 34,5dimethylthiazol2yl2,5diphenyltetrazolium bromide mtt viability assay cck8 dojindo molecular technology inc. tnbc cell line mdamb231 nci diversity set collection compound select structural diversity potential antitumor efficacy screen identify several potential antitumor compound include nsc33353 viability mdamb231 cell reduce 90 data show follow 24 h treatment use 10 08m drug panel ten human breast cancer cell line represent luminal her2 amplify tnbc cell mcf10a tnbc patientderived xenograft pdx model tu4qxtb screen test antiproliferative effect nsc33353 mtt assay perform gauge antiproliferative effect small molecule inhibitor nsc33353 moreover maximize relevance vivo condition also grow cell 3d spheroid closely mimic tumor microenvironment provide better model anticancer treatment traditional 2d culture 36. treatment within range nsc33353 concentration inhibit cell growth 2d fig 1ac 3d culture condition fig 1d dosedependent manner 24 h treatment furthermore halfmaximal inhibitory concentration ic50 value determine every cell line fig 1b observe nsc33353 mainly selective exhibit potent activity average ic50 value cell death induction 2.7 08m tnbc cell line versus nontnbc cell comparison use mcf7 model luminal mdamb453 model her2amplified bc mcf10a cell represent normal breast cell average ic50 nsc33353 nontnbc target 4.4 μm fig 1b fact nsc33353 lower ic50 experiment fdaapproved antimetastatic olaparib 37 38 suggest vivo ic50 similar olaparib might clinically achievable give lack successful target therapy currently available treatment tnbc superior clinical relevance use pdx oppose cell line assess drug response cancer 39 make result clinically relevant test hypothesis use tnbc breast cancer pdx model tu4qxtb data show nsc33353 significantly suppress 4qxtb cell proliferation clonogenic capacity refer renewal potential longterm response cell treatment accord previously describe method capacity cell survive proliferate follow drug treatment determine 40. colony formation assay result demonstrate nsc33353 reduce clonogenic survival mdamb231 lm24175 sum159pt mdamb468 tnbc cell fig 1e f. immortalize cell detachment extracellular matrix induce anoikis particular type apoptosis 41. acquisition resistance anoikis prerequisite tnbc cell survive progress 42. data show nsc33353 diminish anoikis resistance mdamb231 lm24175 sum159pt mdamb468 tnbc cell fig 1g fig s9 gain insight possible mechanism underlie toxic activity cell growth repression nsc33353 first effect nsc33353 cell cycle progression mdamb231 lm24175 sum159pt mdamb468 cell assess flow cytometry treatment nsc33353 induce cell apoptosis show increase proportion tnbc cell subg1 phase cell cycle dosedependent manner cell 24 h treatment fig s1a b. data indicate nsc33353 reduce viability tnbc cell cell cycle arrest subg1 phase next determine effect nsc33353 expression gene regulate cell cycle cdk46 kinase associate cyclin protein transition g1 phase cell cycle cyclin dcdk46 complex phosphorylates retinoblastoma protein rb dissociate e2f transcription factor ultimately responsible cell cycle progression 43. therefore drug target cdk46 garner special interest anticancer therapy moreover tumor suppressor p15 cdkn2b inhibit cdk46 activity 44. cyclindependent kinase 2 cdk2 drive progression cell mphases cell cycle 45. cyclin d1 show overexpressed mrna protein level 50 breast cancer 46 47. furthermore activate cdk1cyclin b complex pivotal mitotic initiation target cyclin b1 inhibit proliferation sensitize breast cancer cell taxol treatment 48. examine effect nsc 33353 pathway show nsc33353 reduce mrna level ccnd1 cdk2 cdk4 ccnd1 increase expression level cdkn2b tnbc cell fig s1c understand mechanism use proteomics strategy find significant negative enrichment net enrichment score ne 1.6122705 fdr qvalue 0.009 antiapoptotic protein nsc33353 treat lm24175 cell show discoverybased proteomics approach use tandem mass tag tmt liquid chromatographymass spectrometry lcm fig 2a confirm proteomics data whether decrease tnbc cell viability upon nsc33353 treatment due increase caspasedependent apoptotic response pathway analyze expression cleavage two wellknown specific apoptotic marker poly adpribose polymerase parp caspase 3 cleavage 49. show fig 2b cleavage protein increase dosedependent manner moreover different do nsc33353 induce apoptotic cell death dosedependent manner demonstrate annexin v stain fig 2c fig s7 result suggest decrease cell viability due least part increase caspasedependent apoptosis moreover demonstrate molecular mechanism antitumor effect nsc33353 therapyresistant tnbc cell investigate effect nsc33353 expression proapoptotic antiapoptotic prosurvival gene tnbc cell often modulate program cell death upregulating antiapoptotic protein bcell clllymphoma 2 bcl2 family one family member myeloid cell leukemia1 mcl1 commonly amplify tnbc correlate poor clinical prognosis 50. correlation among bax protein p53 caspase3 likely associate active apoptotic mechanism breast cancer cell bax protein bclxl frequently overexpressed breast cancer 51. bclxl important member bcl2 family group apoptosis regulator 52. family protein involve network complicate interaction regulate cell fate upstream mitochondrion maintain deathinducing factor cytochrome c 53. puma induce apoptosis activate multidomain proapoptotic protein bax andor bak interaction antiapoptotic bcl2 family member thereby trigger mitochondrial dysfunction caspase activation 54. finally myc overexpressed basallike subtype may target aggressive subtype breast cancer 55. consistent regulation proapoptotic effector upregulation antiapoptotic factor commonly find advance cancer cell resistant apoptosis inhibitor apoptosis protein iap family include ciap1 ciap2 member group apoptosis inhibitor 56. overexpression iap family member cancer cell line primary tumor suggest important role protein cancer progression 57. member iaps include survivin xiap frequently associate poor prognosis drug resistance neoplastic mammary cell 58,59,60,61,62. nsc33353 inhibit mrna level bclxl mcl1 birc2 birc3 xiap myc birc5 increase expression bax pum mdr1 atp bind cassette subfamily b member 1 dosedependent manner tnbc cell fig 2d data suggest nsc33353 enhance apoptosis tnbc cell epithelial mesenchymal transition emt execute emtactivating transcription factor include snail twist zeb family member emt allow solid tumor play critical role cancer progression include tumor initiation primary tumor growth invasion metastasis colonization resistance therapy 63 64. accordingly gain insight possible inhibitory effect nsc33353 cell migration invasion proteomics wholetranscriptome analysis total rna sequence rnaseq data analyze interestingly find significant negative enrichment emt marker drugtreated mdamb231 cell versus dmso control treat cell fig 3a furthermore mdamb231 sum185pt breast cancer cell subject woundhealing assay use 1 μm concentration nsc33353 relatively nontoxic cell treatment cell nsc33353 result timedependent reduction cell migration compare control fig s2a b. addition mdamb231 lm24175 sum185pt cell treat low concentration 0.5 μm 1 μm nsc33353 24 h. transwell migration analysis reveal exposure nsc33353 strongly suppress cell migration dosedependent manner fig 3b similarly nsc33353 treat tnbc cell le invasive untreated counterpart fig 3c expect invasion detect mdamb468 cell however cell migration inhibit nsc 33353 fig s10 inhibitory effect nsc33353 invasion migration mdamb231 sum185pt cell correlate change expression emt marker detect western blot qrtpcr fig 3d e. change ecadherin vimentin zeb1 protein expression nsc33353treated tnbc cell confirm western blot analysis addition treatment nsc33353 decrease expression ncadherin βcatenin bcatenin tnbc cell fig 3d gene expression level zeb1 zeb2 snai slug vim vimentin fn1 fibronectin 1 repress different do nsc33353 tnbc cell expression level cdh1 ecadherin increase fig 3e accordingly immunostaining analysis reveal nsc33353 downregulated mesenchymal marker ncadherin upregulated epithelial marker ecadherin tnbc cell fig 3f previously mdamb468 cell show inducible model emt vitro 65. induce emt phenotype use egf 10 25 ngml induce emt mimic vivo condition 24 h cell observe microscope morphological change observe untreated cell close contact however egf treatment mdamb468 cell lose contact cell attain spindleshaped phenotype fig s2c also emtinduced mdamb468 cell show loss ecad expression fig s2c investigate inhibitory effect nsc33353 emtinduced mdamb468 cell treat cell different do nsc33353 check morphological change 24 h treatment result show nsc33353 treatment emt reversal phenotype reduce number spindlelike cell fig s2d qrtpcr data show emt reprogramming induce nsc33353 might result decrease zeb2 fn1 gene expression level fig s2e find suggest nsc33353 could effectively inhibit invasion migration suppress emtpromoting factor tnbc probe molecular mechanism novel compound evaluate phenotypic difference gene protein expression level analyze discoverybased rnasequencing rnaseq tandem mass tag tmt liquid chromatographymass spectrometry lcm data identify distinct gene protein expression profile mdamb231 lm24175 nsc33353 treatment gene set enrichment analysis gsea 66 reveal upregulated gene mdamb231 lm24175 negatively enrich glycolysis oxphos fig 4 upon nsc 33353 treatment test dependency tnbc cell glycolysis oxphos select list gene know play key role glycolysis oxphos investigate expression across major molecular subtypes breast cancer 67. glucose transporter 1 glut1 essential protein encode slc2a1 gene play critical role glucose metabolism pathway foster cell glucose 63. previously show intensive glucose uptake common characteristic tnbc 68 69. example glut1 protein overexpression significantly correlate tnbc cell proliferation invasion 68 69. usp6nl gtpaseactivating protein elevate expression tnbc inhibition promote glut1 degradation 70. cmyc interact hif1α support metabolic rewire tnbc cell promote tumorigenesis 71. myc overexpression see 40 tnbc connect metabolic reprogramming tumorigenesis 72. consistent pyruvate kinase 2 pkm2 isoenzyme lactate dehydrogenase ldha monocarboxylate transporter mcts particularly mct1 nuclear factor erythroid 2 like2 nrf2 also crucial glycolytic phenotype tumor growth tnbc 73,74,75,76. peroxisome proliferatoractivated receptorgamma coactivator 1 alpha pgc1α transcriptional coactivator mitochondrial oxphos biogenesis highly express lung bone metastasis compare liver 77. pgc1α enhance oxphos mitochondrial function foster formation secondary lung metastasis promote emt process rather affect primary tumor growth 29. intensify fatty acid oxidation facilitate oxphos fuel tnbc metastasis transmembrane glycoprotein alpha cubdomain contain protein 1 cdcp1 drive fatty acid oxidation oxphos tnbc metastasis promote metastasis 32. hand autophagyrelated becn1 may negative regulator metabolic rewire favor mammary carcinogenesis 72. cmyc drive glycolytic program repress thioredoxin interact protein txnip key negative regulator glucose uptake aerobic glycolysis exclusively tnbc tumor 78. investigate expression level slc2a1 usp6nl pkm myc usp6nl hif1a cdctp1 ppargc1a becn1 txnip gene tnbc interrogate large publicly available clinical cohort metabric host